Physician profile
Aaron Mitchell Burman
NPI 1497032213
$807.60
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $198 · 2023: $15.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $147.02 | 2021-2022 | |
| Radius Health, INC. | $82.54 | 2021 | |
| Ibsa Pharma INC. | $75.46 | 2021-2022 | |
| Antares Pharma, INC. | $71.66 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $66.70 | 2021-2022 | |
| Clarus Therapeutics INC. | $63.86 | 2021 | |
| Abbvie INC. | $60.81 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $46.29 | 2021-2022 | |
| Pfizer INC. | $39.84 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $38.62 | 2021 | |
| Lilly USA, LLC | $27.55 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.31 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2023 | Dupixent |
| Horizon Therapeutics Plc | $15.28 | 2021 | |
| Vistapharm, INC. | $14.29 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $13.06 | 2021 | |
| Amgen INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Burman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.